Overview

A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.

Status:
NOT_YET_RECRUITING

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to establish the clinical efficacy of APT-001 topical therapy 1.8% in patients with blepharitis as compared to its vehicle control, and to establish that the therapeutic is safe and generally well tolerated by patients.

Phase:

PHASE2

Details

Lead Sponsor:

Aperta Biosciences, LLC

Treatments:

spinosad